ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,728.80
      0.41%
      US Tech 100
      19,528.00
      0.90%
      Dow Jones
      42,052.19
      0.69%
      Brent Oil
      72.905
      0.00%
      Bitcoin
      69,617.55
      0.21%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. Europe
      5. EU

      6. Ab Science (AB) Quote

      Ab Science

      Ab Science (AB)

      AllianceBernstein Holding LP
      1.016
      0.002
      (0.20%)
      Closed November 02 12:30PM
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      Key stats and details

      Current Price
      1.016
      Bid
      0.987
      Ask
      1.018
      Volume
      12,480
      0.99 Day's Range 1.016
      0.88 52 Week Range 4.465
      Market Cap
      52.904M
      Previous Close
      1.014
      Open
      1.01
      Last Trade
      77
      @
      1.016
      Last Trade Time
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      32,315
      Shares Outstanding
      52,071,069
      Dividend Yield
      -
      PE Ratio
      -4.43
      Earnings Per Share (EPS)
      -0.23
      Revenue
      970k
      Net Profit
      -11.99M

      About Ab Science

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.ab-science.com
      Headquarters
      Paris, Paris, Fra
      Founded
      -
      Ab Science is listed in the Pharmaceutical Preparations sector of the Euronext with ticker AB. The last closing price for Ab Science was 1.01 €. Over the last year, Ab Science shares have traded in a share price range of 0.88 € to 4.465 €.

      Ab Science currently has 52,071,069 shares outstanding. The market capitalization of Ab Science is 52.80 € million. Ab Science has a price to earnings ratio (PE ratio) of -4.43.

      Ask ADVFN Intelligence (AI)

      AB Latest News

      More News

      AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease

      AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN...

      October 28 2024
      UK Regulatory

      AB Science reçoit un avis d’acceptation pour le brevet européen couvrant jusqu’en 2040 le masitinib dans le traitement de la drépanocytose

      AB Science reçoit un avis d’acceptation pour le brevet européen couvrant jusqu’en 2040 le masitinib dans le traitement de la drépanocytose COMMUNIQUE DE PRESSE AB SCIENCE REÇOIT UN AVIS...

      October 28 2024
      UK Regulatory

      AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease

      PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN PATENT COVERING MASITINIB UNTIL 2040 IN THE TREATMENT OF SICKLE CELL DISEASE THIS DECISION FURTHER STRENGTHENS MASITINIB’S...

      October 28 2024
      GlobeNewswire Inc.

      AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

      AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE APPLICATION FOR CONDITIONAL...

      October 17 2024
      UK Regulatory

      AB Science fait le point sur la demande d'autorisation de mise sur le marché conditionnelle du masitinib dans la SLA

      AB Science fait le point sur la demande d'autorisation de mise sur le marché conditionnelle du masitinib dans la SLA COMMUNIQUE DE PRESSE AB SCIENCE FAIT LE POINT SUR LA DEMANDE...

      October 17 2024
      UK Regulatory

      AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS

      PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Paris, 17 October, 2024...

      October 17 2024
      GlobeNewswire Inc.

      AB Science : Résultats financiers semestriels au 30 juin 2024 et point sur les activités d’AB Science

      AB Science : Résultats financiers semestriels au 30 juin 2024 et point sur les activités d’AB Science          COMMUNIQUE DE PRESSE AB SCIENCE PRÉSENTE SES RÉSULTATS FINANCIERS AU PREMIER SEMESTRE...

      October 10 2024
      UK Regulatory

      AB Science: Revenues for the first half of 2024 and update on AB Science’s activities

      AB Science: Revenues for the first half of 2024 and update on AB Science’s activities          PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2024 AND THE KEY EVENTS...

      October 10 2024
      UK Regulatory

      AB Science: Revenues for the first half of 2024 and update on AB Science’s activities

               PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL RESULTS FOR THE FIRST HALF OF 2024 AND THE KEY EVENTS OF THE PERIOD Clinical development Masitinib platform: Ongoing re-examination by...

      October 10 2024
      GlobeNewswire Inc.

      AB Science annonce avoir réalisé le règlement livraison de sa dernière augmentation de capital de 5,0 millions d’euros

      AB Science annonce avoir réalisé le règlement livraison de sa dernière augmentation de capital de 5,0 millions d’euros COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE AVOIR REALISE LE REGLEMENT LIVRAISON...

      October 09 2024
      UK Regulatory
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10.033.042596348880.9861.050.946460000.99409721DE
      40.0181.803607214430.9981.050.88376970.97437854DE
      120.066.276150627620.9561.0780.88323150.99548391DE
      26-0.88-46.41350210971.8962.2950.88785681.40219382DE
      52-1.324-56.58119658122.344.4650.881030712.28505412DE
      156-12.034-92.21455938713.0513.340.88952984.80193443DE
      260-2.384-70.11764705883.421.750.881472238.4083372DE

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      ALAVEAventador
      0.0018 €
      (28.57%)
      		93.77M
      ALARFAdeunis
      0.698 €
      (21.18%)
      		673
      BIOSBiosenic
      0.0078 €
      (18.18%)
      		3.7M
      ALDUBEncres Dubuit
      2.60 €
      (18.18%)
      		15.97k
      MLNOVNovatech Ind
      10.50 €
      (17.32%)
      		32
      MLSMLSmalto
      0.0115 €
      (-25.81%)
      		658
      MLACTActivium Group
      1.60 €
      (-24.53%)
      		11
      ALVERVergnet
      0.0067 €
      (-20.24%)
      		9.37M
      FURFugro NV
      17.64 €
      (-16.24%)
      		2.96M
      ALKALKALRAY SA
      0.984 €
      (-15.17%)
      		209.31k
      ALAVEAventador
      0.0018 €
      (28.57%)
      		93.77M
      ALNEVNeovacs
      0.0002 €
      (0.00%)
      		65.01M
      BCPBanco Comercial Portugues SA
      0.4631 €
      (-0.06%)
      		61.48M
      ALDOLDolfines
      0.0006 €
      (0.00%)
      		48.27M
      ALNRGEnergisme SA
      0.0066 €
      (-8.33%)
      		15.91M

      Discussion

      View Full Feed
      marcis marcis 5 minutes ago
      Together at the hour hotel near the railroad track end of town
      IGPK
      Hoskuld Hoskuld 5 minutes ago
      " it was a fail as dosed didn't beat placebo" this is actually not true Jose. Rett therapy worked, but the placebo group had some outliers and the trial was not large enough (the placebo group specifically was too small) to make those exceptions irrelevant.
      AVXL
      nickeli54 nickeli54 5 minutes ago
      Headed to Snakes in Chicago tonight 💪
      FUNN
      learningcurve2020 learningcurve2020 5 minutes ago
      True, she put many in Cognate and Advent. 
      NWBO
      Rodney5 Rodney5 6 minutes ago
      At a 99% diluted share price calculates $2.27 per share.

      Earnings Power $227.22 per share minus 99% = $2.27

      Fridays closing price $1.30 at $2.27 per share is a 57% return on investment.
      FNMA
      stink stack stink stack 6 minutes ago
      If a certain candidate loses the bottom is going to fall out of this like a wet cardboard box!
      GLTA
      FNMA
      WinstonCup WinstonCup 6 minutes ago
      All we need is one CEO to do ONE job well. So far we haven't seen that here.
      imo
      WDLF
      Zardiw Zardiw 6 minutes ago
      It is unbelievably IRONIC that the usa is so Strongly intent on spreading 'Democracy' around the world..........when we are apparently INCAPABLE of holding Fair Elections ourselves...........lol.........it's so amazing isn't it?

      Z
      PonkenPlonken PonkenPlonken 6 minutes ago
      super action............ to the finish line
      VKTX
      Omar8 Omar8 6 minutes ago
      DP,


      "So omar.......... you've been quiet for a few weeks.......have you abandoned your bashing and your ant will save the day?"



      I'm looking into other stuff while the wait continues, will ANT save the day ? I don't know, I hope he does, what othe
      NNLX
      Moonboy1 Moonboy1 7 minutes ago
      Getting closer to the 12th. Will be loading dips until then and then dumping in the pump after earnings. This never holds up no matter how good the earnings are. But it's good for a nice flip.
      BOF
      Hosai Hosai 7 minutes ago
      Well I would suggest many here understand that 74 year old early AD/MCI patients are very likely to cognitively deteriorate at some point in a 48 week trial even if not in a perfect straight line. You seem to be arguing it was "unfair" because the placebo group fell and made the dosed look better.
      AVXL
      prototype_101 prototype_101 7 minutes ago
      The company’s (LWLG) innovative efforts were recognized at ECOC 2024, where Lightwave Logic received the Industry Award for Most Innovative Hybrid PIC/Optical Integration Platform. This accolade, bestowed by a committee of industry peers, marks the second consecutive year the company has won this aw
      LWLG
      slapy52 slapy52 8 minutes ago
      20,000,050
      ELTP
      Golden Cross Golden Cross 8 minutes ago
      🚀 $ILLR Triller Creating The Next-Gen Entertainment Platform.
      https://x.com/triller_IR/status/1851972390349087224
      ILLR
      tigerpac tigerpac 9 minutes ago
      Based on their quarterly cash burn it appear the company will be out of cash by the end of the year.

      IMO future dilution is on the horizon in order to raise money. If you noticed the accrued expense amounts just keep going higher.
      FRZT
      marcis marcis 9 minutes ago
      Milesblue I like that handle

      It’s a fact after September 2021 OTC has shown its bottom side.

      There are many unsophisticated but making $$$ off garbage stocks.

      They don’t care about any fact or anything in the matter of company interests

      Th
      RONN
      HGilS HGilS 9 minutes ago
      Hi longs. Any volunteer to run our guessing game?

      I am too busy this quarter. I should be good next quarter. Sharkey? Nas?

      Reminder: the shorts do not crown the real winner if they don’t like him or her. And they ignore guesses of some of us. This is the only reaso
      ELTP
      PonkenPlonken PonkenPlonken 9 minutes ago
      maybe they will release the data on the 10q. Would be a nice opportunity to follow up on future funding given they canceled their atm offering in the summer.
      They delayed this readout for so long, coupled with sheer optimism in their replies. I think they will want to include some patients th
      MRKR
      SparklingNavigator24 SparklingNavigator24 10 minutes ago
      From what I can tell you are the one doing the Gas Lighting and the jury is still out on Merck. If the MTD was denied we would learn who is doing what to whom. But I have resigned myself that the judge is waiting for the election on that one.
      NWBO
      trunkmonk trunkmonk 10 minutes ago
      When they just appear, and say stuff like ur the best or ask a specific question to the Circus members, it’s fake, just attempts to validate something. Just like Democrats in Deep state, it’s a Hollywood show of lies and deception. Reality=recap and release.
      plexrec plexrec 10 minutes ago
      "ost a final loss in 2024, before turning a profit of US$80m in 2025…."--good to read george---thanks for posting !!!!
      AVXL

      Your Recent History

      EU
      AB
      Ab Science
      TSXV
      APGO
      Apollo Silver
      BIT
      P16AP7
      BNP Paribas Issuance
      BIT
      S31864
      Societe Generale Effekten
      BIT
      SFIB5L
      SG ISSUER
      NYSE
      DBRG
      DigitalBridge
      TSXV
      CTS
      Converge Technology Solu...
      NYSE
      BHC
      Bausch Health Companies
      TSXV
      ROR
      NASDAQ
      PYPD
      PolyPid
      BIT
      SMOT
      Ucits Etfs
      NYSE
      KEYS
      Keysight Technologies
      USOTC
      SPMYY
      Spirent Communications (PK)
      NASDAQ
      CRVO
      CervoMed
      BIT
      UC567G
      Unicredit Bank
      TSX
      CYB
      Cymbria
      Delayed Upgrade Clock